Crisp polypeptides as contraceptives and inhibitors of sperm capacitation

ABSTRACT

Included in the present invention are methods of inhibiting sperm capacitation, inhibiting the phosphorylation of a protein at tyrosine residues, inhibiting an acrosomal reaction, and inhibiting fertilization of an egg by sperm with the administration of a CRISP polypeptide.

This application claims the benefit of the U.S. Provisional Application Ser. No. 60/383,628, filed May 28, 2002, which is incorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT RIGHTS

This invention was made with government support under a grant from the National Institutes of Health, Grant No. HD 11962. The U.S. Government has certain rights in this invention.

BACKGROUND

An effective, safe and easily reversible male contraceptive with universal acceptability remains an elusive goal. Although a variety of approaches for achieving male contraception have been tried, no single mode of male contraception is without its immediate drawbacks for efficacy or compliance. Even seemingly simple interventions have not proven to be widely acceptable. For example, surgical or non-surgical vasectomy, methods that interrupt sperm transport in the male reproductive tract, are not without their complications or long-term risk. More complex approaches, such as regimens for the hormonal control of male fertility, have also not been fully satisfactory. Such methods have focused on the suppression of spermatogenesis to the point of azoospermia, a goal that has been difficult to achieve. The use of the immune response to block contraception has been an important front in efforts to develop more sophisticated contraceptive systems. Unfortunately, such approaches have thus far failed, as male autoimmunity against sperm does not suppress sperm production in men; this is known because such autoimmunity can occur after vasectomy. Thus, inhibiting sperm fertilizing-ability without affecting the hormonal balance in either the male or female remains an important goal in the field of reproductive biology. The present invention achieves this goal.

SUMMARY OF THE INVENTION

The present invention includes a method of inhibiting sperm capacitation including contacting sperm with a CRISP polypeptide. Also included in the present invention is a method of inhibiting sperm capacitation in an individual including the administration of a CRISP polypeptide to the individual.

In another aspect, the present invention also includes a method for inhibiting fertilization of an egg by sperm in an individual, comprising the administration of a CRISP polypeptide to the individual.

In another aspect, the present invention includes a method of inhibiting the phosphorylation of a protein at tyrosine residues including contacting the protein with a CRISP polypeptide. In some embodiments of the present invention, the protein may be on the surface of mammalian sperm.

A further aspect of the present invention includes a method of inhibiting an acrosomal reaction including contacting the acrosomal reaction with a CRISP polypeptide.

In some embodiments of the methods of the present invention, the CRISP polypeptide may be administered orally. In some embodiments of the methods of the present invention, the CRISP polypeptide may be administered parenterally. In some embodiments of the methods of the present invention, the CRISP polypeptide may be administered transdermally. In some embodiments of the methods of the present invention, the CRISP polypeptide may be administered in a composition including a pharmaceutically acceptable carrier.

In some embodiments of the methods of the present invention, the individual may be a mammalian male. In some embodiments of the methods of the present invention, the individual may be a mammalian female. In some embodiments of the methods of the present invention, the CRISP polypeptide may be administered intravaginally, including administered as a time released, vaginal implant. In other embodiments of the methods of the present invention, the CRISP polypeptide is administered to the vagina of the mammalian female in an amount capable of inhibiting sperm capacitation, rendering said sperm incapable of fertilization.

In other embodiments of the methods of the present invention, the CRISP polypeptide has at least about 40% structural identity to a polypeptide selected from the group consisting of human CRISP-1 (SEQ ID NO:1, rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6), mouse CRISP-3 (SEQ ID NO:7), and biologically active analogs thereof.

In yet other embodiments of the methods of the present invention, the CRISP polypeptide has at least about 40% structural identity to human CRISP-1 (SEQ ID NO:1) or a biologically active analog thereof. In some embodiments of the methods of the present invention, the CRISP polypeptide is human CRISP-1 (SEQ ID NO:1).

In other embodiments of the methods of the present invention, the CRISP polypeptide has about at least 40% structural identity to rat CRISP-1 (SEQ ID NO:2) of a biologically active analog thereof. In some embodiments of the methods of the present invention, the CRISP polypeptide is rat CRISP-1 (SEQ ID NO:2).

Also included in the present invention is a contraceptive composition including a CRISP polypeptide in an amount effective to inhibit sperm capacitation, inhibit phosphorylation of a protein at tyrosine residues, inhibit an acrosome reaction, and/or inhibit fertilization of an egg by sperm. In some embodiments of the contraceptive composition of the present invention, the CRISP polypeptide has at least about 40% structural identity to a polypeptide selected from the group consisting of human CRISP-1 (SEQ ID NO:1, rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6), mouse CRISP-3 (SEQ ID NO:7) and biologically active analogs thereof. In some embodiments of the contraceptive composition of the present invention, the CRISP polypeptide has at least about 40% structural identity to human CRISP-1 (SEQ ID NO:1) and biologically active analogs thereof. In some embodiments of the contraceptive composition of the present invention, the CRISP polypeptide is human CRISP-1 (SEQ ID NO:1). In some embodiments of the contraceptive composition of the present invention, the CRISP polypeptide has at least about 40% structural identity to rat CRISP-1 (SEQ ID NO:2), and biologically active analogs thereof. In other embodiments of the contraceptive composition of the present invention, the CRISP polypeptide is rat CRISP-1 (SEQ ID NO:2). In some embodiments of the contraceptive composition of the present invention, the contraceptive composition further includes a spermicidal or an antiviral agent.

DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1. Immunoblot of solubilized rat sperm collected from the end of the epididymis and incubated in a defined capacitation medium in vitro for 5 hours under controlled conditions. A sample of sperm was taken at the beginning of incubation to provide the time zero conditions (lane 1). Aliquots of collected sperm were incubated under the following various conditions: 5 hours under non-capacitation conditions (lane 2); 5 hours under capacitating conditions (lane 3); and 5 hours under capacitating conditions with increasing concentrations of CRISP-1 (lanes 4, 5, and 6). In FIG. 1A, the immunoblot is stained with an anti-phosphotyrosine antibody. FIG. 1B shows the same gel stained with an anti-CRISP-1 antibody.

FIG. 2. The requirement of incubating rat sperm with bovine serum albumin (BSA) to achieve the tyrosine phosphorylation associated with capacitation. Rat epididymal sperm were isolated in BWW with (+BSA) or without (−BSA) 15 mg/ml lipid-rich BSA for 5 hours. Aliquots of sperm were checked for tyrosine phosphorylation at 1, 3, and 5 hour time points by western blot analysis using an anti-phosphotyrosine antibody (FIG. 2A). A steady accumulation of tyrosine phosphorylation was observed in the presence of BSA, with negligible phosphorylation in BWW alone. To determine if extraction of cholesterol was the action of the BSA that led to the tyrosine phosphorylation, sperm were incubated with 15 mg/ml BSA with (Ch) or without (B) the addition of 30 μM cholesterol sulfate and tyrosine phosphorylation compared to levels seen in sperm incubated in BWW alone (C). The addition of exognenous cholesterol sulfate eliminated the BSA-induced phosphorylation of sperm proteins (FIG. 2B).

FIG. 3. The comparative activity of lipid-rich BSA and Fraction V BSA in the induction of protein tyrosine phosphorylation of rat and mouse sperm. Rat epididymal sperm were incubated in increasing concentrations of lipid-rich (LR) or Fraction V (F5) BSA and protein tyrosine phosphorylation was determined after 5 hours (FIG. 3A). Both lipid-rich and Fraction V BSA showed maximal induction of phosphorylation at 15 mg/ml, but phosphorylation was greatest in lipid-rich BSA at each concentration. Since Fraction V BSA is routinely used for capacitation studies in other species, 4 mg/ml lipid-rich or Fraction V BSA were tested in capacitation incubations with mouse sperm (FIG. 3B). With mouse sperm, both lipid-rich and Fraction V are equipotent at inducing protein tyrosine phosphorylation.

FIG. 4. The requirement of extracellular Ca⁺⁺ for induction of capacitation in rat sperm. Sperm were incubated in BWW solution with (+Ca⁺⁺) or without (−Ca⁺⁺) 1.7 mM Ca⁺⁺. At hourly time points out to 4 hours, sperm were tested for the presence of tyrosine-phosphorylated proteins. The presence of extracellular calcium ion was required for maximal phosphorylation.

FIG. 5. The requirement of extracellular bicarbonate ion for induction of capacitation in rat sperm. Sperm were incubated in BWW solution with (+) or without (−) 25 mM HCO₃ ⁻ for 4 hours and then tested for the presence of tyrosine-phosphorylated proteins. The presence of bicarbonate ion in the media was required for tyrosine phosphorylation of sperm proteins. Omission of bicarbonate resulted in phosphorylation levels the same as BWW alone (C).

FIG. 6. Quantitative kinetics of cholesterol extraction and protein tyrosine phosphorylation of sperm proteins. Rat epididymal sperm were incubated in 1 or 2 mM methyl-β-cyclodextran (MBCD) and extracted cholesterol measured at time intervals out to 2 hours (FIG. 6A). The levels of cholesterol were determined by the Amplex Red Cholesterol assay and the results normalized to cholesterol extracted in BWW alone. Protein tyrosine phosphorylation was measured by western blot at hourly time points during extraction with MBCD (FIG. 6B). Cholesterol extraction reached a plateau with 1 mM MBCD at 30 minutes and with 2 mM MBCD between 60 and 120 minutes (later time points not shown). Maximal phosphorylation lagged behind maximal cholesterol extraction with both concentrations of MBCD.

FIG. 7. The effect of incubation of rat epididymal sperm with exogenous purified Crisp-1 on the level of protein tyrosine phosphoryation. Sperm were incubated under capacitating conditions with 15 mg/ml lipid-rich BSA for 5 hours in the presence of increasing concentrations (μg/ml) of purified proteins DE (FIG. 7A). Analysis of cells prior to capacitation incubation are shown as control (C). At 400 μg/ml protein tyrosine phosphorylation was nearly completely inhibited. The same Western blot was stripped and probed with antibody CAP-A (FIG. 7B) and 4E9 (FIG. 7C). Protein detected by CAP-A demonstrates that Crisp-1 re-associates with the sperm in a dose dependent fashion that correlates with the inhibition of capacitation (FIG. 7B). Antibody CAP-A detects all forms of Crisp-1 including processed forms of proteins D and E. Monoclonal antibody 4E9 detects only forms of Protein E (FIG. 7C). Comparison of the staining with 4E9, which stains only a processed form of protein E extracted from the sperm surface, and CAP-A demonstrates that only an unprocessed form of protein D re-associates with sperm to inhibit phosphorylation. The unprocessed Crisp-1 detected by CAP-A is lost with time when the sperm are removed from the exogenous pure Crisp-1 solution, suggesting that unprocessed Crisp-1 associates in a receptor-ligand fashion while processed Crisp-1 is covalently attached to the sperm surface.

FIG. 8. The effect of incubation of rat epididymal sperm with exogenous purified Crisp-1 on the level of progesterone induced acrosome reaction. Sperm were incubated under capacitating conditions for 1 hours in the presence or absence of 400 μg/ml Crisp-1. Progesterone (P4) at 1 μM was added to sperm after 30 minutes of incubation to induce the acrosome reaction. DMSO, the solvent used for the P4 stock solution, was added to control cells. Addition of P4 to capacitated sperm (+BSA+P4) caused a statistically significant (*P<0.05) increase in acrosome reacted sperm compared to capacitated sperm (+BSA or +BSA+DMSO). This increase is completely abolished by addition of exogenous Crisp-1 (+BSA+P4+CRISP-1), as evidenced by the statistically significant decrease (*P<0.05) in acrosome reacted sperm. Columns are shown with values at base. The percent acrosome reacted sperm in the +BSA+P4 group was significantly higher (*P<0.05) than all other groups and there was no significant difference in the percent acrosome reacted sperm between any of the other groups. Data are presented as means +/−SEM.

FIG. 9. The reversibility of protein tyrosine phosphoryation inhibition by exogenous purified Crisp-1 in rat epididymal sperm. Sperm were incubated under capacitating conditions with 15 mg/ml lipid-rich BSA for 5 hours in the presence (lane 4) or absence (lane 3) of 200 μg/ml Crisp-1. At 5 hours sperm were washed free of exogenous Crisp-1 and incubated for an additional 3 (lane 5) or 19 (lane 6) hours. Sperm at time zero and after 5 hours in BWW without BSA are shown in lanes 1 and 2, respectively. Sperm proteins were analyzed by western blot analysis for protein tyrosine phosphorylation (FIG. 9A) and Crisp-1 (FIG. 9B). As shown previously, 200 μg/ml Crisp-1 has an inhibitory effect on sperm protein tyrosine phosphorylation. The inhibition of protein tyrosine phosphorylation was reversed with the removal of Crisp-1. Exogenous Crisp-1 associated with sperm after 5 hours incubation is lost from the surface of sperm with time. An aliquot of purified Crisp-1 used in the sperm incubations is shown in lane 7.

FIG. 10. Effect of exogenous administration of cAMP analog, dibromo-cAMP (db-cAMP), and the phosphodiesterase inhibitor IBMX on the protein tyrosine phosphorylation associated with capacitation. To determine if BSA, Ca⁺⁺, and HCO₃ ⁻ act upstream of cAMP in the signaling cascade that leads to protein tyrosine phosphorylation (FIG. 10A), sperm were incubated in the presence (lanes 4, 6, 8) or absence (lanes 3, 5, 7) of db-cAMP/IBMX without BSA (lanes 3, 4), Ca⁺⁺ (lanes 5, 6), or HCO₃ ⁻ (lanes 7, 8). Control phosphorylation in BWW or BWW with BSA are shown in lanes 1 and 2, respectively. In each case, exogenous cAMP and IBMX overcome the block to phosphorylation caused by omission of BSA, Ca⁺⁺, or HCO₃ ⁻ from the capacitation medium, indicating that cAMP acts downstream for the effect of these three required constituents of capacitation. The ability of cAMP to overcome the inhibition of phosphorylation by Crisp-1 was tested by incubating sperm under capacitating conditions with and without db-cAMP/IBMX in the presence of 400 μg/ml pure Crisp-1 (lanes 3 & 4, respectively, FIG. 10B). Control sperm in BWW only or BWW with BSA are shown in lanes 1 and 2, respectively. The results show that the block to phosphorylation caused by Crisp-1 is also upstream of the effect of cAMP on protein tyrosine phosphorylation.

FIG. 11. Amino acid sequence of human CRISP-1 (SEQ ID NO:1), rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6) and mouse CRISP-3 (SEQ ID NO7).

FIG. 12. cDNA sequences encoding human CRISP-1 (SEQ ID NO:8), rat CRISP-1 (SEQ ID NO:9), mouse CRISP-1 (SEQ ID NO:10), human CRISP-2 (SEQ ID NO:11), rat CRISP-2 (SEQ ID NO:12), human CRISP-3 (SEQ ID NO:13) and mouse CRISP-3 (SEQ ID NO:14).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

With the present invention it has been demonstrated that a CRISP polypeptide inhibits sperm capacitation, inhibits protein phosphorylation at tyrosine residues, and inhibits the acrosomal reaction. Thus, CRISP polypeptides can be used in improved methods of contraception, without affecting or interfering with the hormonal or immune systems. The CRISP polypeptides of the present invention include naturally occurring CRISP polypeptides and biologically active analogs thereof.

Naturally occurring CRISP polypeptides comprise a family of Cysteine-RIch Secretory Proteins that are expressed in numerous organs in male animals, particularly in the reproductive tract. CRISP polypeptides are not generally expressed in female animals, with the exception of neutrophils, and possibly in tumors. In the male, CRISP-1 is expressed primarily in the epididymis, CRISP-2 is expressed primarily in the testis and CRISP-3 is expressed primarily in salivary glands. Prostate and seminal vesicles also have low expression of some of these proteins. Sperm require passage through the epididymis before they are able to fertilize an egg. This passage is an obligatory maturational process in the male and during this time, CRISP-1, a secretory product of the epididymis, is added to the sperm surface. When sperm are ejaculated into the female reproductive tract they under go a process called “capacitation,” which is required as the final maturational step before interaction between sperm and egg. It is well recognized that sperm that are not capacitated win not fertilize. Thus, the identification of agents that inhibit capacitation will lead to development of improved contraceptives.

The CRISP family of polypeptides has been extensively characterized and the amino acid sequences of the CRISP-1, CRISP-2 and CRISP-3 polypeptides from a number of species are known. The CRISP-1 polypeptides from human (Kratzschmar et al., Eur. J. Biochem. 236(3):827-36, 1996), rat (Klemme et al., Gene 240(2):279-88, 1999; Charest et al., Mol. Endocrinol. 2 (10), 999-1004, 1988; Brooks et al., Eur. J. Biochem 161(1):13-18, 1986), and mouse (Eberspaecher et al., Mol. Reprod. Dev. 42:157-172, 1995; Haendler et al., Endocrinology 133 (1), 192-198, 1993) have been characterized. The human CRISP-1 amino acid sequence (SEQ ID NO:1) is available as Genbank Accession Number CAA64524, the rat CRISP-1 amino acid sequence (SEQ ID NO:2) is available as Genbank Accession Number AAD41529, and the mouse CRISP-1 amino acid sequence (SEQ ID NO:3) is available as Genbank Accession A49202, all of which are shown in FIG. 11. The cDNA sequence encoding human CRISP-1 (SEQ ID NO:8) is available as Genbank Accession Number X95237, the cDNA sequence encoding rat CRISP-1 (SEQ ID NO:9) is available as Genbank Accession Number NM_(—)022859, and the cDNA sequence encoding mouse CRISP-1 (SEQ ID NO:10) is available as Genbank Accession Number L05559, all of which are shown in FIG. 12.

The CRISP-2 polypeptides from human (Kratzschmar et al., Eur. J. Biochem. 236 (3), 827-836, 1996) and rat (O'Bryan et al., Mol. Reprod. Dev. 50 (3), 313-322, 1998) have been characterized. The human CRISP-2 amino acid sequence (SEQ ID NO:4), available as Genbank Accession Number P16562, and the rat CRISP-2 amino acid sequence (SEQ ID NO:5), available as Genbank Accession Number AAD48090, are shown in FIG. 11. The cDNA sequence encoding human CRISP-2 (SEQ ID NO:11) is available as Genbank Accession Number X95239 and the cDNA sequence encoding rat CRISP-2 (SEQ ID NO:12) is available as Genbank Accession Number AF078552, all of which are shown in FIG. 12.

The CRISP-3 polypeptides from human (Kratzschmar et al., Eur. J. Biochem. 236 (3), 827-836, 1996) and mouse (Haendler et al., Endocrinology 133 (1), 192-198 (1993)) have been characterized. The human CRISP-3 amino acid sequence (SEQ ID NO:6), available as Genbank Accession Number P54108, and the mouse CRISP-3 amino acid sequence (SEQ ID NO:7), available as Genbank Accession Number Q03402, are shown in FIG. 11. The cDNA sequence encoding human CRISP-3 (SEQ ID NO:13) is available as Genbank Accession Number X95240 and the cDNA sequence encoding mouse CRISP-3 (SEQ ID NO:14) is available as Genbank Accession Number L05560, all of which are shown in FIG. 12.

The CRISP polypeptides of the present invention may be derived from a variety of species, including, but not limited to, human, primate, rat, mouse, bovine, and horse. The CRISP polypeptides of the present invention include, but are not limited to, CRISP-1, CRISP-2 and CRISP-3 polypeptides. For example, the CRISP polypeptides of the present invention include, but are not limited to, human CRISP-1 (SEQ ID NO:1), rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO: 6), and mouse CRISP-3 (SEQ ID NO:7).

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide, whether naturally occurring or synthetically derived, for instance, by recombinant techniques or chemically or enzymatically synthesized. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. The following abbreviations are used throughout the application:

-   A=Ala=Alanine T=Thr=Threonine -   V=Val=Valine C=Cys=Cysteine -   L=Leu=Leucine Y=Tyr=Tyrosine -   I=Ile=Isoleucine N=Asn=Asparagine -   P=Pro=Proline Q=Gln=Glutamine -   F=Phe=Phenylalanine D=Asp=Aspartic Acid -   W=Trp=Tryptophan E=Glu=Glutamic Acid -   M=Met=Methionine K=Lys=Lysine -   G=Gly=Glycine R=Arg=Arginine -   S=Ser=Serine H=His=Histidine

As used herein, a CRISP polypeptide also includes “biologically active analogs” of naturally occurring CRISP polypeptides. For example, the CRISP polypeptides of the present invention include, but are not limited to, biologically active analogs of human CRISP-1 (SEQ ID NO:1), rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6), or mouse CRISP-3 (SEQ ID NO:7).

As used herein to describe a CRISP polypeptide, the term “biologically active” means to inhibit protein tyrosine phosphorylation, inhibit sperm capacitation, inhibit an acrosome reaction, and/or inhibit fertilization of an egg by sperm. Biological activity of a CRISP polypeptide can be easily assessed using the various assays described herein as well as other assays well known to one with ordinary skill in the art. An inhibition in biological activity can be readily ascertained by the various assays described herein, and by assays known to one of skill in the art. An inhibition in biological activity can be quantitatively measured and described as a percentage of the biological activity of a comparable control. The biological activity of the present invention includes an inhibition that is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, at least about 100%, at least about 110%, at least about 125%, at least about 150%, at least about 200%, at least or about 250% of the activity of a suitable control.

A “biologically active analog” of a CRISP polypeptide includes polypeptides having one or more amino acid substitutions that do not eliminate biological activity. Substitutes for an amino acid in the polypeptides of the invention may be selected from other members of the class to which the amino acid belongs. For example, it is well-known in the art of protein biochemistry that an amino acid belonging to a grouping of amino acids having a particular size or characteristic (such as charge, hydrophobicity and hydrophilicity) can be substituted for another amino acid without altering the activity of a protein, particularly in regions of the protein that are not directly associated with biological activity. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of such preferred conservative substitutions include Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free —OH is maintained; and Gln for Asn to maintain a free NH2. Likewise, biologically active analogs of a CRISP polypeptide containing deletions or additions of one or more contiguous or noncontiguous amino acids that do not eliminate the biological activity of the CRISP polypeptide are also contemplated.

A “biologically active analog” of a CRISP polypeptide includes “fragments” and “modifications” of a CRISP polypeptide. As used herein, a “fragment” of a CRISP polypeptide means a CRISP polypeptide that has been truncated at the N-terminus, the C-terminus, or both. The CRISP protein family is characterized by sixteen-conserved cysteine residues located within the C-terminus of the polypeptide. A “fragment” of a CRISP polypeptide may include 1, 2, 3, 4, 5 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 of the conserved cysteine residues of the CRISP protein family. A fragment may range for about 5 to about 250 amino acids in length. For example it may be about 5, about 10, about 20, about 25, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, or about 250 amino acids in length. Fragments of a CRISP polypeptide with potential biological activity can be identified by many means. One means of identifying such fragments of a CRISP polypeptide with biological activity is to compare the amino acid sequences of a CRISP polypeptide from rat, mouse, human and/or other species to one another. Regions of homology can then be prepared as fragments.

A “modification” of a CRISP polypeptide includes CRISP polypeptides or fragments thereof chemically or enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified polypeptides of the invention may retain the biological activity of the unmodified polypeptide or may exhibit a reduced or increased biological activity.

The CRISP polypeptides and biologically active analogs thereof of the present invention include native (naturally occurring), recombinant, and chemically or enzymatically synthesized polypeptides. For example, the CRISP polypeptides of the present invention may be prepared following the procedures for the isolation of CRISP-1 polypeptide from rat sperm detailed by Hall and Tubbs (Prep. Biochem. Biotechnol. 27(4):239-51, 1997). For example, the CRISP polypeptides of the present invention can be prepared recombinantly, by well known methods, including, for example, preparation as fusion proteins in bacteria and insect cells.

As used herein, the term “isolated” means that a polynucleotide or polypeptide is either removed from its natural environment or synthetically derived, for instance by recombinant techniques, or chemically or enzymatically synthesized. An isolated polynucleotide denotes a polynucleotide that has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Isolated polynucleotides of the present invention are free of other coding sequences with which they are ordinarily associated, but may include naturally occurring 5′ and 3′ untranslated regions such as promoters and terminators. Preferably, the polynucleotide or polypeptide is purified, i.e., essentially free from any other polynucleotides or polypeptides and associated cellular products or other impurities.

As used herein, “structural similarity” refers to the identity between two polypeptides. Structural similarity is generally determined by aligning the residues of the two polypeptides to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. For example, polypeptides may be compared using the Blastp program of the BLAST 2 search algorithm, as described by Tatusova et al. (FEMS Microbiol. Lett., 174; 247-250, 1999) and available on the world wide web at ncbi.nlm.nih.gov/BLAST/. The default values for all BLAST 2 search parameters may be used, including matrix=BLOSUM62; open gap penalty=1, extension gap penalty=1, gap x_dropoff=50, expect=10, wordsize=3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity may be referred to by percent “identity” or may be referred to by percent “similarity.” “Identity” refers to the presence of identical amino acids and “similarity” refers to the presence of not only identical amino acids but also the presence of conservative substitutions.

The CRISP polypeptides of the present invention include polypeptides with at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% structural identity to a known rat, mouse or human CRISP polypeptide. The CRISP polypeptides of the present invention also include polypeptides with at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% structural similarity to a known rat, mouse or human CRISP polypeptide.

For example, the CRISP polypeptides of the present invention may include, but are not limited to, polypeptides with at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% structural identity to human CRISP-1 (SEQ ID NO:1), rat CRISP-1 (SEQ ID NO:2), or mouse CRISP-1 (SEQ ID NO:3). For example, the CRISP polypeptides of the present invention may also include, but are not limited to, polypeptides with at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% structural similarity to human CRISP-1 (SEQ ID NO:1), rat CRISP-1 (SEQ ID NO:2), or mouse CRISP-1 (SEQ ID NO:3).

According to the present invention, a CRISP polypeptide, including biologically active analogs thereof, can be administered to a subject in an effective amount sufficient to inhibit protein phosphorylation at tyrosine residues, inhibit sperm capacitation, inhibit an acrosome reaction, and/or inhibit the fertilization of an egg by sperm. The CRISP polypeptides of the present invention may be administered to a male or female individual. The individual may be a mammal, including, but not limited to a mouse, rat, primate, bovine, or human. For example, in one embodiment of the present invention, a CRISP-1 polypeptide, or a biologically active analog thereof, can be administered to a subject in an effective amount sufficient to inhibit protein phosphorylation at tyrosine residues, inhibit sperm capacitation, inhibit an acrosome reaction, and/or inhibit the fertilization of an egg by sperm.

As used herein an “acrosome reaction” or “acrosomal reaction” includes the sequence of structural changes that occur in spermatozoa when in the vicinity of an oocyte. Such structural changes serve to facilitate entry of a spermatozoon into the oocyte and include the fusion of portions of the outer membrane of the acrosome with the plasma membrane of the sperm head, creating openings through which the enzymes of the acrosome are released. See, for example, Wasserman et al., Nat. Cell Biol. 3:9-14, 2001.

By the term “effective amount” of an agent as provided herein is meant a nontoxic but sufficient amount of the agent or composition to provide the desired effect. Thus, in the context of the present invention, an “effective amount” of a CRISP polypeptide is an amount sufficient to inhibit protein phosphorylation at a tyrosine residue, inhibit sperm capacitation, inhibit an acrosome reaction, and/or affect contraception. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, and the particular agent and its mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation. Therapeutically effective concentrations and amounts may be determined for each application herein empirically by testing the compounds in known in vitro and in vivo systems, such as those described herein; dosages for humans or other animals may then be extrapolated therefrom.

In some embodiments of the present invention, a CRISP polypeptide may be delivered by intravaginal administration. For such administration, a CRISP polypeptide may be provided as a cream gel, foam, emulsion, suppository, and the like. In certain embodiments of the present invention, CRISP polypeptides may be contained within a time released vaginal implant.

In some embodiments of the present invention, a CRISP polypeptide may be delivered by oral administration. For such oral administration, a CRISP polypeptide may be provided as a liquid, a tablet, a pill, a capsule, a gel coated tablet, a syrup, or some other oral administration method. In certain embodiments of the present invention, CRISP polypeptides may be contained within a bio-erodible matrix for time-controlled release.

In some embodiments of the present invention, a CRISP polypeptide may be delivered by transdermal administration. For such administration, a CRISP polypeptide may be provided as a cream, a transdermal patch, and the like. In certain embodiments of the present invention, CRISP polypeptides may be contained within a time released composition.

In some embodiments of the present invention, a CRISP polypeptide may be delivered by parenteral administration. For such administration, a CRISP polypeptide may by provided in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, intraperitoneal, and intratumoral administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure (see for example, “Remington's Pharmaceutical Sciences” 15th Edition). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by the FDA.

In some aspects, the present invention includes contraceptive compositions including an effective amount of a CRISP polypeptide, or a biologically active analog thereof, in an amount effective to inhibit sperm capacitation, inhibit protein tyrosine phosphorylation, inhibit an acrosome reaction, and/or effect contraception. These contraceptive compositions may contain one or more active agents. For example, such contraceptive compositions may include, one or more CRISP polypeptides. Such contraceptive compositions may include one or more additional active agents that are not a CRISP polypeptide. Such active agents may include, but are not limited to, spermicidal agents and/or antiviral agents.

The CRISP polypeptides of the present invention may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the desired therapeutic outcome and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be treated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions and methods. The agents of the present invention may be administered to the subject in combination with other modes of contraception. The agents of the present invention can be administered before, during or after the administration of the other therapies.

The CRISP polypeptides of the present invention may be formulated in a composition along with a “carrier.” As used herein, “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with a CRISP polypeptide without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

A “subject” or an “individual” is an organism, including, for example, a mammal. A mammal may include, for example, a rat, mouse, a primate, a domestic pet, such as, but not limited to, a dog or a cat, livestock, such as, but not limited to, a cow, a horse, and a pig, or a human. Subject also includes model organisms, including, for example, animal models, used to study fertilization of an egg by sperm, sperm capacitation, protein tyrosine phosphorylation, or the acrosome reaction.

A “control” sample or subject is one in which a CRISP pathway has not been manipulated in any way.

As used herein in vitro is in cell culture, ex vivo is a cell that has been removed from the body of a subject and in vivo is within the body of a subject. Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one.

The present invention also includes an isolated molecule, the molecule being present on the sperm plasma membrane and binds to a CRISP polypeptide. The molecule may be an isolated component of a calcium channel or a receptor involved in calcium channel signaling. For example, the isolated molecule may be a molecule being present on the sperm plasma membrane and binds to a CRISP-1 polypeptide, or a biologically active analog, fragment, or modification thereof. This molecule that binds to a CRISP-1 polypeptide may be an isolated component of a calcium channel or a receptor involved in calcium channel signaling.

EXAMPLES

The present invention is illustrated by the following example. It is to be understood that the particular example, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

Example 1 Role of CRISP Proteins in the Regulation of Sperm Capacitation and Use in Contraception

The results of Example 1 are shown in FIG. 1. Rat sperm were collected from the end of the epididymis and incubated in a defined capacitation medium in vitro for 5 hours under controlled conditions. A sample of sperm was taken at the beginning of incubation to provide the time zero conditions (lane 1 of FIG. 1). Aliquots of collected sperm were incubated under the following various conditions:

-   -   For 5 hours under non-capacitation conditions (lane 2 of FIG. 1)     -   For 5 hours under capacitating conditions (lane 3 of FIG. 1)     -   For 5 hours under capacitating conditions with increasing         concentrations of CRISP-1 (lanes 4, 5 and 6 of FIG. 1).         At the end of incubation, sperm were solubilized and solubilized         sperm proteins were separated by SDS gel electrophoresis.         Proteins were then transblotted onto a membrane and treated with         a primary anti-phosphotyrosine antibody. The results of this         anti-phosphotyrosine western blot are shown in FIG. 1A. After         recording the results with the anti-phosphotyrosine antibody,         the transblot was striped of antibodies and re-probed with an         antibody against CRISP-1. The results of this anti-CRISP-1         western blot are shown as FIG. 1B.

FIG. 1A shows phosphotyrosine distribution in sperm under the various incubation conditions. Under non-capacitating conditions, there appears to be some phosphorylation activity. This phosphorylation activity is significantly increased under capacitation conditions, with numerous different proteins exhibiting phosphorylation. Phosphorylation activity is inhibited on many proteins by the addition of CRISP-1. FIG. 1B shows the same gel stained with an anti-CRISP-1 antibody. In lane 1 (time zero) one can see two bands (the D form and the E form of CRISP-1). Under both non-capacitating and capacitating conditions, the D form of CRISP-1 is lost from sperm (see lanes 2 and 3). When CRISP-1 is added back (see lanes 4, 5 and 6), the D form re-appears in a dose-dependent fashion. The E form, which is also present in the added CRISP-1 protein, remains constant under all experimental conditions.

Thus, the addition of CRISP-1 to the capacitating incubation medium inhibits protein tyrosine phosphorylation, a universal indicator of capacitation.

Example 2 Inhibition of Capacitation-Associated Tyrosine Phophorylation Signaling in Rat Sperm by Epididymal Protein Crisp-1

In mammals, development of fertilizing ability and progressive motility by sperm, the process of post-testicular maturation, begin as sperm are moved through the male reproductive tract and are completed when sperm are deposited in the female reproductive tract and undergo capacitation.

In the male post-testicular duct system, sperm acquire new proteins and glycoproteins on their surfaces and undergo numerous biochemical changes during their passage through the ducts that make them capable of vigorous, directed movement and able to fertilize an egg (Yanagimachi R. Mammalian Fertilization. The Physiology of Reproduction 1994: 186-317). Crisp-1 (DE, AEG) is a glycoprotein couplet (comprised of protein D and protein E, hereinafter referred to collectively as Crisp-1) that is secreted by the epididymal epithelium (Brooks and Higgins, Journal of Reproduction & Fertility 1980; 59: 363-375; Moore et al, Molecular Reproduction & Development 1994; 37: 181-194) and associates with the sperm surface (Rochwerger and Cuasnicu, Molecular Reproduction & Development 1992; 31: 3441; Xu et al, Mol Reprod Dev 1997; 46: 377-382.). A portion of the Crisp-1 on the sperm surface, in particular Protein E, is proteolytically-processed (Roberts et al, Biology of Reproduction 2002; 67: 525-533). Crisp-1 is one of many epididymis-secreted proteins that associate with sperm (Faye et al, Biol Reprod 1980, 23: 423-432; Kohane et al, Biol Reprod 1980, 23: 737-742; Moore, J Exp Zool 1981, 215: 77-85 (1981); Wong and Tsang, Biol Reprod 1982, 27: 1239-1246; Tezon et al, Biol Reprod 1985, 32: 591-597; Iusem et al, Biol Reprod 1989, 40: 307-316; Vreeburg et al., Bull Assoc Anat (Nancy) 1991, 75: 171-173; Rankin et al., Biology of Reproduction 1992, 46: 747-766; Boue et al, Biol Reprod 1996, 54: 1009-1017). The mechanism(s) of the interaction (e.g., covalent bonds, charge effects, hydrophobic bonds) between the sperm plasma membrane and extracellular epididymal molecules is unknown, but is likely to be varied. In contrast seminal vesicle secretions that are known to participate in capacitation in mice (Huang et al., Biol Reprod 2000, 63: 1562-1566 (2000); Huang et al., Biochem J 1999, 343 Pt 1: 241-248; Luo et al, J Biol Chem 2001 276: 6913-6921) and bulls (Huang et al, Biol Reprod 2000, 63: 1562-1566 (2000); Huang et al, Biochem J 1999, 343 Pt 1: 241-248; Luo et al., J Biol Chem 2001, 276: 6913-6921) are added to the cell surfaces after ejaculation by binding to sperm plasma membrane phospholipid head groups. In rats there is evidence that seminal vesicle proteins are added to the sperm surface (Manco and Abrescia, Gamete Res 1988, 21: 71-84; Manco et al., Eur J Cell Biol 1988, 47: 270-274), possibly by transglutaminase activity in semen (Paonessa et al., Science 1984, 226: 852-855), and it has been reported also that a prostate-derived protein binds to rat spermatozoa (Sansone and Abrescia, J Exp Zool 1991, 259: 379-385). Thus, addition of proteins and glycoproteins derived from different parts of the duct to sperm surfaces occurs throughout the male excurrent duct system.

Under normal conditions ejaculated sperm are unable to fertilize an egg until they have resided in the female tract for a number of hours (the time varies from species to species (Bedford, Biol Reprod 1970, 2: Suppl 2:128-158; Davis, Proc Natl Acad Sci USA 1981, 78: 7560-7564), and have undergone capacitation. Capacitation was independently, and virtually simultaneously, described in two laboratories (Austin, Australian Journal of Scientific Research, B 1951, 4: 581-589; Chang, Nature 1951, 168: 697) as the time required for sperm to penetrate an egg after having been deposited in the female reproductive tract. Residence in the female tract is required for capacitation in vivo, resulting in the acquisition of hyperactivated motility in many, but not all species; the loss or changes in some constituents of the plasma membrane, including proteins and glycoproteins and in the acquisition of the ability to undergo the acrosome reaction.

During the more than half century since its discovery, capacitation has been the subject of intense investigation, particularly since it is possible to capacitate sperm in vitro and use them to fertilize an egg. Common themes about what happens during capacitation are beginning to emerge. In all species that have been examined, it is necessary for cholesterol to be removed from the membrane, which can be accomplished in vitro by incubating sperm in a medium containing serum albumin (Davis, Proc Soc Exp Biol Med 1976, 151: 240-243; Davis et al., Proc Natl Acad Sci USA 1980, 77: 1546-1550) or other cholesterol-binding agents such as cyclodextrins (Choi and Toyoda, Biol Reprod 1998, 59: 1328-1333; Visconti et al., Biol Reprod 1999, 61: 76-84). Cholesterol removal results in a cAMP-dependent tyrosine phosphorylation of a number of proteins, both in the sperm plasma membrane and in intracellular structures such as the axoneme and fibrous sheath. Initiation and completion of capacitation is absolutely dependent on extracellular Ca⁺⁺ and HCO₃ ⁻, in addition to a cholesterol sequestering agent.

In this example we report the results of experiments designed to elucidate the conditions required for in vitro capacitation of rat spermatozoa and the effects of Crisp-1, an epididymal secretory protein, on capacitation. We demonstrate that protein tyrosine phosphorylation, a hallmark of capacitation in other species' sperm, occurs during five hours of in vitro incubation and that this phosphorylation is dependent upon cAMP. HCO₃ ⁻, Ca⁺⁺, and the removal of cholesterol from the membrane. We also show that Crisp-1, added to the sperm surface in the epididymis in vivo, is lost during capacitation and that addition of exogenous Crisp-1 to the incubation medium inhibits tyrosine phosphorylation in a dose dependent manner, and thus inhibits capacitation and ultimately the acrosome reaction. We further show that the inhibition of capacitation by Crisp-1 is upstream of the production of cAMP by the sperm.

Materials and Methods

Chemicals and Reagents: Anti-Phosphotyrosine (4G10) monoclonal IgG conjugated to horseradish peroxidase (HRP) was purchased from Upstate Biotechnology Inc. (Lake Placid, N.Y.). ALEXA FLUOR 488 goat anti-rabbit IgG, AMPLEX Red Cholesterol Assay Kit and Slow-Fade were purchased from Molecular Probes (Eugene, Oreg.). Cold water fish skin gelatin (40% solution) was purchased from Electron Microscopy Sciences (Washington, Pa.). SUPER SIGNAL West Pico Chemiluminescent Substrate was purchased from Pierce Chemical Co. (Rockford, Ill.). ALBUMAX I lipid-rich bovine serum albumin (BSA) was purchased from Gibco BRL (Grand Island, N.Y.). Original and modified BWW were purchased from Irvine Scientific (Santa Ana, Calif.). All other chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, Mo.). Generation of the CAP-A anti-peptide polyclonal antibody and the 4E9 monoclonal antibody have been previously described (Moore et al., Molecular Reproduction & Development 1994, 37:181-194; Roberts et al., Biology of Reproduction 2002, 67: 525-533).

Media: The base media used for collection and experimental incubation of sperm was original formula BWW medium (Biggers et al, Methods in Mammalian Embryology 1971, 86-116). BWW minus calcium or bicarbonate was prepared according to the recipe reported by Biggers, et. al. (1971) (Biggers et al, Methods in Mammalian Embryology 1971, 86-116). Sperm were capacitated in BWW with 15 mg/ml ALBUMAX I lipid-rich BSA, unless otherwise noted. Other cholesterol acceptor molecules included Fraction V BSA and methyl-β-cyclodextrin, and were added to BWW in some experiments.

Sperm Collection and Preparation: Spague-Dawley male retired breeder rats were euthanized by CO₂ asphyxiation and epididymes were surgically removed. Radial slits were made in each of the cauda epididymes followed by a 5 minute incubation in 1 ml of BWW buffered with 21 mM HEPES on an orbital shaker to facilitate the swim out of sperm into the media. The sperm suspensions were placed in a 1.5 ml microcentrifuge tube, leaving behind the epididymes, and gently shaken by hand to ensure an even concentration of sperm. Sperm counts were performed using a hemacytometer. Aliquots of approximately 3.5×10⁶ sperm were diluted into 0.5 ml of capacitation medium that was pre-equilibrated overnight at 37° C. in 5% CO₂. The incubation wells were overlayed with 0.5 ml of mineral oil and incubated for times indicated (in figure legends) at 37° C. in 5% CO₂. Subjective assessment of sperm motility showed minimal decreases during capacitation incubation. All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Minnesota.

SDS-PAGE and Western Blotting: Samples were prepared for SDS-PAGE analysis using a modification of the protocol described by Visconti et. al., (1995). Briefly, sperm were collected from under oil and centrifuged at 16,000×g in microcentrifuge tubes for 5 minutes immediately following the capacitation incubation. The sperm pellet was washed twice with 1 ml of phosphate buffered saline (PBS) and resuspended in 100 μl of 1× Laemmli sample buffer (Laemmli. Nature 1970, 227: 680-685). The samples were vortexed for 15 seconds, heated to 95° C. for 5 minutes and centrifuged at 16,000×g to remove insoluble material. Supernatants were transferred to new tubes, reduced by the addition of β-mercaptoethanol (to a final concentration of 2.5%) and heated again to 95° C. for 5 minutes. 20 μl of each sample, equivalent to 7×10⁵ sperm, were subjected to polyacrylamide gel electrophoresis (PAGE) on tris-glycine gels (7.5%, 12% or 15%, depending on the experiment). Proteins were transferred to Immobilon P membrane (Millipore, Bedford, Mass.) at 100 volts for 1 hour at 4° C.

For detection of tyrosine-phosphorylated proteins, blots were blocked with 6.5% fish skin gelatin in TBS-T (Tris Buffererd Saline with 0.1% Tween 20) for 30 minutes followed by incubation with anti-phosphotyrosine-HRP antibody (1:15,000), in blocking solution, for 1 hour at room temperature. The blots were washed with TBS-T, followed by incubation with HRP substrate (Super Signal West Pico) for 5 minutes. Blots were exposed to X-ray film for 5 to 30 seconds. Western blot detection of the protein D and E forms of Crisp-1 with anti-peptide antibody CAP-A and monoclonal antibody 4E9 were done as previously described (Moore et al., Molecular Reproduction & Development 1994, 37: 181-194; Roberts et al., Biology of Reproduction 2002, 67: 525-533.).

Immunocytochemistry: Sperm were stained immunocytochemically with anti-peptide antibody CAP-A and monoclonal antibody 4E9 essentially as previously described (Moore et al., Molecular Reproduction & Development 1994; 37: 181-194). Briefly, sperm were washed 3× in BWW to remove media, fixed with Bouin's fixative for 30 minutes and washed extensively with PBS. Cells were blocked for 30 minutes with 1% BSA/PBS and antibodies were added for an hour incubation at room temperature. The anti-peptide antibody CAP-A was used at a dilution of 1:200 while mAb 4E9 was used at 1:1000. Sperm were washed 3× with PBS and Alexa-Fluor 488 anti-rabbit antibody was added to the CAP-A tubes while anti-mouse—FITC was added to the 4E9 tubes. After incubation for 1 hour in Alexa-Fluor second antibody at room temperature, cells were washed with PBS mounted on slides in Slow-Fade® and viewed using a Nikon fluorescent microscope.

Cholesterol Assay: Total lipids were extracted from BWW containing MBCD after incubation with sperm essentially as described by Bligh and Dyer (Bligh and Dyer, Canadian Journal of Biochemistry and Physiology 1959, 37: 911-917). Briefly, after incubating sperm with BWW/MBCD, sperm were removed by centrifugation and 0.8 ml of supernatant was recovered. Chloroform and methanol were added to the supernatant, with vortexing, to a final ratio of chloroform to methanol to aqueous supernatant of 2:2:1.8. After vigorous vortexing, the final mixture was centrifuged for 5 minutes at 600×g and one ml of the organic (lower) phase was removed to a new tube. The lipids in the organic phase were dried under a stream of desiccated nitrogen and stored at −20° C.

Cholesterol was measured in the extracted lipid samples using the Amplex Red Cholesterol Assay Kit, according to the manufacturers instructions. Briefly, dried lipid samples were resuspended in 50 μl of reaction buffer and mixed 1:1 with working solution containing 300 μM Amplex Red reagent, 2 U/ml horseradish peroxidase, 2 U/ml cholesterol oxidase and 2 U/ml cholesterol esterase in wells of a 96-well microtiter plate. A standard curve was prepared using the cholesterol reference standard provided with the kit. All samples were incubated for 2 hrs at 37° C. Fluorescence of reaction product was measured at various time points in a FL600 Microplate Reader (BIOTEK Instruments, Inc., Winooski, Vt.) with an excitation filter of 530 nm and an emission filter of 590 nm.

Acrosome reaction and staining: The acrosome reaction and assessment of acrosomal status was performed essentially as described by Bendahmane et al. (Bendahmane et al., Arch Biochem Biophys 2002, 404: 38-47). Following incubation under capacitating or non-capacitating conditions for 30 minutes, progesterone (P4), dissolved in DMSO, was added to a final concentration of 1 μM. After an additional 30 minutes of incubation, sperm were fixed in 4% paraformaldehyde, washed and dried on slides. To visualize the acrosome, the sperm were stained with 0.22% Coomassie blue G-250 solution for 2 minutes, rinsed with distilled water and allowed to air dry. Slides were coverslipped using Permount mounting media and observed under a Nikon brightfield microscope at a magnification of 600×. For each condition within an experiment, 500 cells were assessed for acrosomal status.

Statistical Analysis: All experiments reported in the manuscript were repeated a minimum of three times. Raw data from the acrosome reaction experiments were subjected to the Tukey analysis for determination of statistically significant differences (P<0.05) between pairs of all treatment groups.

Results

Initial studies were carried out to characterize the dependence of rat sperm capacitation on the presence of a cholesterol binding molecule, Ca⁺⁺ and HCO₃ ⁻; the three components shown to be requirements of capacitation in most other species. Capacitation conditions for rat sperm were tested using tyrosine phosphorylation of sperm proteins as an indication of the extent of the capacitation process. FIG. 2A demonstrates, by western blot with an antibody against phosphotyrosine, the dependence of capacitation on incubation with a lipid-accepting molecule, in this experiment bovine serum albumin (BSA). In the presence of 15 mg/ml lipid rich BSA, protein tyrosine phosphorylation on sperm proteins increased over 5 hours of incubation. Cholesterol was determined to be the lipid responsible for capacitation since incubation with exogenous cholesterol sulfate inhibited protein tyrosine phosphorylation (FIG. 2B).

Initial capacitation experiments were carried out in solution of a 15 mg/ml lipid-rich BSA (Gibco-BRL), a concentration of BSA routinely used in our BWW solution for in vitro fertilization. Because most capacitation experiments are conducted using fraction V BSA, we compared the efficacy of using lipid-rich or fraction V BSA at various concentrations. FIG. 3A demonstrates that lipid-rich BSA was superior to fraction V for inducing tyrosine phosphorylation in rat sperm at all concentrations investigated. In fact, incubation of sperm with fraction V BSA gave very low levels of tyrosine phosphorylation in rat sperm. When the same comparison was performed using mouse sperm, where fraction V BSA is routinely used, the efficacy of tyrosine phosphorylation was the same (FIG. 3B). These results suggest that different BSA preparations have different effects on sperm depending on the species. The basis for this difference is not clear.

The dependence of rat sperm capacitation on exogenous Ca⁺⁺ is shown in FIG. 4. Incubation in the absence of exogenously added Ca⁺⁺ for 4 hours was accompanied by minimal tyrosine phosphorylation compared to sperm incubated in the presence of 1.7 mM Ca⁺⁺. The level of tyrosine phosphorylation in the absence of exogenous Ca⁺⁺ was higher than that seen in the absence of BSA, which may be attributable to trace amounts of Ca⁺⁺ in the medium or to the availability of Ca⁺⁺ from intracellular sources. Likewise, capacitation was shown to be dependent on the presence of bicarbonate ion in the medium by assessing protein tyrosine phosphorylation in the presence and absence of HCO₃ ⁻ (FIG. 5). Solutions in this experiment were buffered with HEPES buffer to insure that the requirement of bicarbonate was not simply due to its buffering capacity in the medium.

To examine the relationship between cholesterol removal from the sperm plasma membrane and the protein tyrosine phosphorylation events associated with capacitation, sperm were incubated with two doses of the cholesterol-binding molecule methyl-β-cyclodextran (MBCD). During incubation with MBCD, cholesterol was removed from the sperm in a dose-dependent fashion. MBCD at 2 mM removed twice as much cholesterol as 1 mM MBCD (FIG. 6A). When protein tyrosine phosphorylation was measured, phosphorylation in 2 mM MBCD was increased in both kinetics and total amount over that observed with 1 mM MBCD (FIG. 6B). Protein tyrosine phosphorylation lagged behind the removal of cholesterol from the sperm plasma membrane, as indicated by the fact that cholesterol removal was at a plateau within 30 minutes with 1 mM MBCD (FIG. 6A) yet no increase in phosphorylation was observed until 2 hours (FIG. 6B). These results indicated that protein tyrosine phosphorylation is dependent on cholesterol removal in a dose dependent fashion, but that the kinetics of cholesterol removal is not rate limiting to the phosphorylation process.

The removal of cholesterol from cell membranes has been shown to affect the organization of lipid micro-domains, or rafts, which in turn can affect signaling events in the cell (Simons, Nat Rev Mol Cell Biol 2000, 1: 31-39). To determine if the removal of cholesterol from rat epididymal sperm might be associated with changes in lipid rafts, sperm were stained with the β subunit of cholera toxin (βCT), which binds to the ganglioside GM₁ (a lipid known to be present in many lipid rafts) before and after cholesterol removal. Rat epididymal sperm were incubated in BWW with or without BSA or MBCD to facilitate the removal of cholesterol from the sperm plasma membrane. After 5 hours the sperm were fixed and stained with a fluorescent-tagged β-subunit of cholera toxin, which binds to the sugar moiety of GM₁. In control sperm at time zero or after 5 hours in BWW only, GM₁ staining is tightly confined to the post-acrosomal and head cap regions of the sperm. After removal of cholesterol by BSA or MBCD, GM₁ staining begins to diffuse over the equatorial region and acrosome, and increased staining is seen on the sperm tail. Immediately after isolation of sperm from the rat epididymis the sperm show very specific staining with βCT over the equatorial segment and the head cap region. This staining pattern remained constant after 5 hours of incubation in BWW devoid of a cholesterol-binding molecule. However, after 5 hours of incubation with 15 mg/ml BSA or 1 mM MBCD, βCT staining became diffuse over the entire sperm head and became visible on the sperm tail. Virtually all of the sperm observed (>99%) underwent this redistribution. This result indicates that lipid microdomains on sperm are disrupted by removal of cholesterol, and raft components, such as GM₁, are redistributed on the surface of the sperm. This redistribution correlates with sperm capacitation, implicating raft-associated signaling events in the capacitation process.

Crisp-1 is a sperm maturation protein secreted in two forms, proteins D and E (Roberts et al., Biology of Reproduction 2002, 67: 525-533., Cameo and Blaquier, Journal of Endocrinology 1976, 69: 47-55; Xu and Hamilton, Mol Reprod Dev 1996, 43: 347-357) by the epididymal epithelium, both of which become bound to the sperm surface during epididymal transit (Moore et al., Molecular Reproduction & Development 1994, 37: 181-194., Brooks and Tiver, Journal of Reproduction & Fertility 1983, 69: 651-657). Studies have shown that the majority of Crisp-1 is lost from sperm during incubation after ejaculation or after incubation of sperm isolated from the epididymis (Tubbs et al., J Androl 2002, 23: 512-521). Staining of the protein D and E forms of Crisp1 by anti-peptide antibody CAP-A and monoclonal antibody 4E9 in the presence or absence of MBCD reveals that CAP-A binds to both the D and E forms of Crisp-1 and localizes to the entire surface of the sperm. With time the staining of sperm with CAP-A becomes less intense in both the absence and, even more so, in the presence of MBCD. The intensity of staining with antibody 4E9, which recognizes only the E form of Crisp-1, does not change with time in BWW and decreases only marginally when the sperm are incubated for 4 hours with MBCD. Staining, with antibodies that differentiate the binding of the protein D and E form of Crisp-1, demonstrates that the majority of the protein D and E forms of Crisp-1 is lost during capacitation incubation, with or without a cholesterol binding agent. However, the protein E form of Crisp-1 remains confined to the tail of the sperm without detectable loss or redistribution during the capacitation process.

Since the loss of the protein D form of Crisp-1 occurs during the time frame of sperm capacitation, it is possible that the presence of exogenous Crisp-1 may inhibit the capacitation process. FIG. 7A shows the effect on protein tyrosine phosphorylation of incubating sperm under capacitating conditions in the presence of increasing concentrations of purified Crisp-1. At a dose of 400 μg/ml, Crisp-1 inhibits almost completely the protein tyrosine phosphorylation associated with capacitation. Re-probing of these western blots with anti-peptide antibody CAP-A, which recognizes all forms of the Crisp-1 proteins, showed that the endogenous D-form of Crisp-1 (protein D at 32 kDa) is lost from the sperm during capacitation and that exogenous protein D becomes associated with the sperm coincident with the inhibition of capacitation (FIG. 7B). When this western blot was probed with a monoclonal antibody 4E9, which recognizes only the E-form of Crisp-1 (protein E at −28 kDa), the blot showed that protein E is not lost from the sperm surface during capacitation and no additional protein E associates with sperm during the incubation with exogenous Crisp-1 (FIG. 7C).

It has been recently reported that the protein E form of Crisp-1 is processed as it associates with sperm in the epididymis and that a portion of the protein D form of Crisp-1 may also be processed as it associates with sperm (Roberts et al., Biology of Reproduction 2002, 67: 525-533). Comparison of FIGS. 7B and 7C demonstrates the presence of a processed form of Crisp-1 that is not recognized by the 4E9 antibody. This observation suggests that the processed forms of Crisp-1 attach permanently to the sperm while the unprocessed form of protein D interacts dynamically with the sperm plasma membrane to reversibly prevent capacitation-associated tyrosine phosphorylation.

If the tyrosine phosphorylation events suppressed by Crisp-1 represent the suppression of capacitation, then Crisp-1 should also be able to inhibit the ability of the cells to undergo an induced acrosome reaction. To test this, rat sperm were capacitated for one hour with 15 mg/ml BSA in the presence or absence of 400 μg/ml Crisp-1 and the acrosome reaction induced with 1 μM progesterone (P4). FIG. 8 shows a significant increase (P<0.05) in the acrosome reaction in capacitated sperm after incubation with P4. This increase was completely suppressed by addition of exogenous Crisp-1. The suppression of the acrosome reaction by Crisp-1 was statistically significant (P<0.05). This result indicates that Crisp-1 is inhibiting capacitation in rat sperm.

The dynamic nature of the interaction between Crisp-1 (unprocessed form) and the sperm surface suggests that the inhibition of protein tyrosine phosphorylation by Crisp-1 may be reversible. To test this possibility, sperm were incubated under capacitating conditions in the presence 200 μg/ml Crisp-1 for 5 hours and then removed to capacitation media devoid of Crisp-1. As the data of FIG. 9A demonstrate, significant suppression of protein tyrosine phosphorylation was observed at 5 hours by Crisp-1. After 3 additional hours of incubation in the absence of Crisp-1, protein tyrosine phosphoryation had resumed and continued out to 24 hours. The resumption of phosphorylation activity correlates with the loss of Crisp-1 from the sperm (FIG. 9B).

Previous studies on the requirements for capacitation in mouse sperm have shown that Ca⁺⁺, HCO₃ ⁻, and removal of cholesterol from the sperm plasma membrane are all required for the protein tyrosine phosphorylation events of capacitation (Visconti et al., Development 1995, 121: 1129-1137). However, the absence of any of these three could be compensated for by the addition of cAMP analogs, demonstrating that cAMP signaling in the sperm is intermediary to protein tyrosine phosphorylation (Visconti et al., Development 1995, 121: 1139-1150). FIG. 10 demonstrates that a similar signaling pathway exists for rat sperm. When sperm were incubated in the presence of the cAMP analog db-cAMP and the phophodiesterase inhibitor IBMX, protein tyrosine phosphorylation occurred in the absence of any of the three molecules required for capacitation (FIG. 10A). Furthermore, stimulation of the cAMP pathway by db-cAMP and IBMX also overcame the inhibition of capacitation caused by exogenous Crisp-1 (FIG. 10B). These results indicate that the signaling pathway leading to capacitation is similar between mouse and rat, and that Crisp-1 inhibits capacitation by intervening in an event upstream of the stimulation of cAMP production by the sperm.

Discussion

This study provides the first characterization of the requirements for capacitation of rat sperm using tyrosine-phosphorylation of sperm proteins as the indication that the capacitation signaling cascade has been activated. As with previous work in other laboratories, primarily using mouse sperm, we have shown that rat sperm capacitation requires the presence of a cholesterol-binding agent, such as BSA, calcium ion, and bicarbonate ion (Visconti et al., Development 1995, 121: 1129-1137; Visconti et al., J Androl 1998, 19: 242-248). Further, the action of all three of these required molecules likely leads to the production of cAMP, as evidenced by the ability of exogenous db-cAMP with the phosphodiesterase inhibitor IBMX to overcome the absence of BSA, Ca⁺⁺ or HCO₃ ⁻, consistent with the results of studies of mouse sperm capacitation (Visconti et al., Development 1995, 121: 1129-1137).

Most, if not all, mammalian sperm require cholesterol removal from the plasma membrane in order for capacitation to occur. However, the mechanism by which cholesterol removal facilitates capacitation in sperm is not known. One likely possibility is that removal of cholesterol from lipid microdomains, or rafts, facilitates the movement of signaling molecules in the plasma membrane, allowing critical interactions that lead to the activation of adenylate cyclase and subsequent tyrosine phosphorylation of target proteins. Several recent studies have provided evidence for the existence of lipid rafts on mouse and guinea pig sperm (Travis et al., Dev Biol 2001, 240: 599-610; Trevino et al., FEBS Lett 2001, 509: 119-125.; Honda et al., J Biol Chem 2002, 277: 16976-16984). We demonstrate here that rat sperm contain discrete regions of staining for binding of cholera toxin β subunit, which binds to the ganglioside GM₁, a common lipid component of membrane rafts. Furthermore, the discrete localization of GM₁ is lost during cholesterol extraction with either BSA or MBCD, suggesting that molecules within the sperm plasma membrane begin to diffuse upon removal of cholesterol. A similar diffusion of lipids in the sperm plasma membrane has been reported in boar sperm during in vitro capacitation (Gadella et al., J Cell Sci 1995, 108 (Pt 3):935-946)).

Our data also show that the degree of tyrosine phosphorylation in rat sperm is dependent upon the extent of cholesterol extraction. The data of FIG. 6 demonstrate that doubling the amount of MBCD used to extract cholesterol from the sperm membrane increases the maximal degree of tyrosine phosphorylation at the 5 hour time point. Increasing MBCD also increases the kinetics of phosphorylation. Taken together these findings suggest that, if liberation of signaling molecules to move in the plasma membrane is the mechanism by which cholesterol extraction works, removing more cholesterol facilitates more interactions and with faster kinetics. However, it is also clear that removal of cholesterol under the conditions of our experiments is not rate limiting to subsequent tyrosine phosphorylation. Using 1 mM MBCD, extraction of cholesterol reached a plateau within 30 minutes, but an increase in tyrosine phosphorylation was not detected until 2 hours and is not maximal until 3 hours. The delay between cholesterol removal and tyrosine phosphorylation is consistent with a requirement for physical redistribution of signaling molecules within the plasma membrane.

The requirement for bicarbonate ion in rat sperm capacitation is consistent with a role for the bicarbonate-dependent soluble adenylate cyclase that has been implicated in the capacitation process in sperm from other mammalian species (Sinclair et al., Mol Reprod Dev 2000, 56: 6-11; Wuttke et al., Jop 2001, 2: 154-158; Flesch et al., J Cell Sci 2001, 114: 3543-3555). A previous study using boar sperm demonstrated that without bicarbonate ion in the media, cholesterol was not lost from the plasma membrane during incubation in the presence of BSA (Flesch et al., J Cell Sci 2001, 114: 3543-3555). The authors of this study proposed that the role of bicarbonate ion was to activate the bicarbonate-dependent adenylate cyclase, which in turn caused the cAMP-dependent activation of flipase, which was required for cholesterol removal from the plasma membrane. In the work presented here, the absence of bicarbonate was overcome by addition of cAMP analog and IBMX, consistent with a capacitation requirement for cAMP downstream of the requirement for bicarbonate ion. However, cholesterol removal from the membrane proceeded normally in the absence of bicarbonate ion, supporting a mechanism of capacitation where cAMP acts downstream of cholesterol removal from the membrane.

Both capacitation and the acrosome reaction are calcium ion dependent functions of mammalian sperm (Visconti et al., J Reprod Immunol 2002, 53: 133-150); Breitbart, Mol Cell Endocrinol 2002, 187: 139-144). Our results demonstrate that exogenous calcium is required for the tyrosine phosphorylation accompanying capacitation, consistent with this requirement shown in earlier studies for other mammalian species (Visconti et al., Development 1995, 121: 1129-1137; Dorval et al., Biol Reprod 2002, 67: 1538-1545). The specific calcium-dependent molecular events of capacitation have not been determined, but the ability to overcome the absence of calcium in the medium with exogenous cAMP analogs suggests that the calcium-dependent events in the sperm are upstream of the activation of adenylate cyclase.

In addition to the requirement for Ca⁺⁺, HCO₃ ⁻, and a cholesterol-binding agent in capacitation, a requirement for the disassociation of Crisp-1 from the sperm membrane for capacitation to proceed in rat sperm has also been demonstrated. It has been demonstrated by immunocytochemistry that a portion of the Crisp-1 staining is lost from the sperm with incubation, primarily from the head region and by western blot analysis that it is the 32 kDa form of Crisp-1 that is lost from the sperm membrane (FIG. 7). The addition of exogenous Crisp-1 inhibits protein tyrosine phosphorylation in a reversible manner, suggesting that Crisp-1 interacts with a specific protein or lipid on the sperm surface, in a dynamic ligand-receptor fashion, and inhibits the capacitation process. Given this effect of Crisp-1 on rat sperm capacitation and the high concentration of Crisp-1 in epididymal fluid, it is likely that Crisp-1 acts as a capacitation inhibiting factor.

Crisp-1 was also shown to inhibit the P4 induced acrosome reaction, supporting the conclusion that Crisp-1 inhibits capacitation and that protein tyrosine phosphorylation is required for capacitation in the rat. The level of induced acrosome reaction is low compared with that seen in other species but is consistent with a previous report for rat sperm (Bendahmane et al., Arch Biochem Biophys 2002, 404: 38-47). The very high level of spontaneous acrosome reactions that occur in rat sperm with time during capacitation, over 75% by 3 hours, make it difficult to measure the induced acrosome reaction at extended time points where phosphorylation is more easily measured.

The mechanism by which Crisp-1 inhibits the progression of rat sperm to capacitation is unknown. However, potential mechanisms of action can be inferred from similarities of this protein to proteins of known function. The primary amino acid sequence of Crisp-1 is highly similar to that of many toxins, in particular the toxin helothermine produced by the lizard Heloderma horridum (Morrissette et al., Biophysical Journal 1995, 68: 2280-2288). Helothermine is known to act as an inhibitor of calcium flux through the ryanodine receptor, a regulated calcium channel in muscle cells (Morrissette et al., Biophysical Journal 1995, 68: 2280-2288). Since calcium is required for capacitation, Crisp-1 may prevent the uptake of needed calcium via channels in the sperm plasma membrane. Ryanodine receptors have been reported to be present in testicular germ cells and sperm, but their exact localization remains unclear (Gianni et al., Journal of Cell Biology 1995, 128: 893-904; Trevino et al., Zygote 1998, 6: 159-172). However, it is certainly plausible that Crisp-1 acts on the sperm by interacting with a ryanodine receptor or a ryanodine receptor-like channel in the sperm plasma membrane.

It appears that Crisp-1 is the only secretory protein of the epididymis to possess capacitation inhibitory activity. However, proteins or factors in secretions of the male reproductive tract with apparent capacitation inhibitory activity have been reported from several species (Huang et al., Biol Reprod 2000, 63: 1562-1566 (2000); Aonuma et al., Chem Pharm Bull (Tokyo) 1976, 24:907-911; Eng and Oliphant, Biol Reprod 1978, 19: 1083-1094; Kanwar et al., Fertil Steril 1979, 31: 321-327; Tomes et al., Mol Hum Reprod 1998, 4: 17-25). The mouse seminal vesicle autoantigen has been shown to inhibit protein tyrosine phosphorylation associated with sperm capacitation and human seminal plasma has been shown to contain a factor(s) with similar activity (Huang et al., Biol Reprod 2000, 63: 1562-1566 (2000); Tomes et al., Mol Hum Reprod 1998, 4: 17-25). Although little is known of the mechanism of capacitation suppression reported in seminal plasma and secretory proteins of the seminal vesicles, it appears that suppression of premature capacitation is an important function of fluids of the male excurrent reproductive tract.

In addition to the 32 kDa form of Crisp-1 that interacts in a reversible way with the sperm plasma membrane to inhibit capacitation, a second smaller molecular weight form is also found on sperm; this form is strongly attached and is not removed during incubation under capacitating conditions. It has been previously shown that both the D and E forms of Crisp-1 are processed (Roberts et al., Biology of Reproduction 2002, 67: 525-533). The processed E form of Crisp-1 is recognized by monoclonal antibody 4E9 and localizes to the sperm tail; its function there is unknown (Roberts et al., Biology of Reproduction 2002, 67: 525-533).

Crisp-1 has been implicated as playing a role in sperm-egg fusion. A number of studies in rat, mouse and human systems have shown that fusion of sperm to the plasma membrane of zona pellucida-free eggs is inhibited in the presence of Crisp-1 (Rochwerger et al., Developmental Biology 1992, 153: 83-90); Cohen et al., Biol Reprod 2000, 63: 462-468, Cohen et al., Biol Reprod 2001, 65: 1000-1005). Further, preincubation of zona pellucida-free eggs with Crisp-1, followed by immunocytochemistry with an antibody specific to Crisp-1, demonstrates specific binding sites for Crisp-1 on the surface of eggs (Rochwerger et al., Developmental Biology 1992, 153: 83-90). Taken together, these studies suggest that Crisp-1 can inhibit sperm-egg fusion and are consistent with the hypothesis that Crisp-1 is involved in sperm-egg fusion. However, there are no known fusogenic domains contained within the amino acid sequence of Crisp-1 and nothing in the predicted tertiary structure of the protein suggests a role in membrane fusion. Therefore, it is unlikely that Crisp-1 mediates the sperm-egg fusion event directly. Given the ability of Crisp-1 to block the signaling cascade leading to capacitation, as shown in the present example, a possible role for Crisp-1 in sperm-egg fusion may involve regulation of signaling events, particularly those associated with protein tyrosine phosphorylation. Processed Crisp-1 remaining on the sperm plasma membrane could interact with signaling molecules on the egg surface to initiate or otherwise regulate the fusion event.

The complete disclosures of all patents, patent applications including provisional patent applications, and publications, and electronically available material (e.g., GenBank amino acid and nucleotide sequence submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been provided for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described; many variations will be apparent to one skilled in the art and are intended to be included within the invention defined by the claims.

Sequence Listing Free Text

-   SEQ ID NO: 1-7 are amino acid sequences. -   SEQ ID NO: 8-14 are cDNA sequences. 

1. A method of inhibiting sperm capacitation comprising contacting said sperm with a CRISP polypeptide.
 2. A method of inhibiting sperm capacitation in an individual comprising administering a CRISP polypeptide to said individual.
 3. A method for inhibiting the fertilization of an egg by sperm in an individual, comprising the administration of a CRISP polypeptide to said individual.
 4. A method of inhibiting the phosphorylation of a protein at tyrosine residues comprising contacting said protein with a CRISP polypeptide.
 5. The method of claim 4, wherein said protein is on the surface of mammalian sperm.
 6. A method of inhibiting an acrosomal reaction comprising contacting the acrosomal reaction with a CRISP polypeptide.
 7. The method of claim 2, wherein said CRISP polypeptide is administered orally.
 8. The method of claim 2, wherein said CRISP polypeptide is administered parenterally.
 9. The method of claim 2, wherein said CRISP polypeptide is administered transdermally.
 10. The method of claim 2, wherein said CRISP polypeptide is administered in a composition comprising a pharmaceutically acceptable carrier.
 11. The method of claim 2, wherein said individual is a mammalian male.
 12. The method of claim 2, wherein said individual is a mammalian female.
 13. The method of claim 12, wherein said CRISP polypeptide is administered intravaginally.
 14. The method of claim 12, wherein said CRISP polypeptide is administered as a time released, vaginal implant.
 15. The method of claim 12, wherein said CRISP polypeptide is administered to the vagina of the mammalian female in an amount capable of inhibiting sperm capacitation, rendering said sperm incapable of fertilization.
 16. The method of claim 1 wherein the CRISP polypeptide has at least about 40% structural identity to a polypeptide selected from the group consisting of human CRISP-1 (SEQ ID NO:1, rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6), mouse CRISP-3 (SEQ ID NO:7), and biologically active analogs thereof.
 17. The method of claim 1 wherein the CRISP polypeptide has at least about 40% structural identity to human CRISP-1 (SEQ ID NO:1), or a biologically active analog thereof.
 18. The method of claim 1 wherein the CRISP polypeptide is human CRISP-1 (SEQ ID NO:1).
 19. The method of claim 1 wherein the CRISP polypeptide has about at least 40% structural identity to rat CRISP-1 (SEQ ID NO:2), or a biologically active analog thereof.
 20. The method of claim 1 wherein the CRISP polypeptide is rat CRISP-1 (SEQ ID NO:2).
 21. A contraceptive composition comprising a CRISP polypeptide in an amount effective to inhibit sperm capacitation, inhibit phosphorylation of a protein at tyrosine residues, inhibit an acrosome reaction, and/or inhibit the fertilization of an egg by sperm.
 22. The contraceptive composition of claim 21 wherein the CRISP polypeptide has at least about 40% structural identity to a polypeptide selected from the group consisting of human CRISP-1 (SEQ ID NO:1, rat CRISP-1 (SEQ ID NO:2), mouse CRISP-1 (SEQ ID NO:3), human CRISP-2 (SEQ ID NO:4), rat CRISP-2 (SEQ ID NO:5), human CRISP-3 (SEQ ID NO:6), mouse CRISP-3 (SEQ ID NO:7) and biologically active analogs thereof.
 23. The contraceptive composition of claim 21 wherein the CRISP polypeptide has at least about 40% structural identity to human CRISP-1 (SEQ ID NO:1), or a biologically active analog thereof.
 24. The contraceptive composition of claim 21 wherein the CRISP polypeptide is human CRISP-1 (SEQ ID NO:1).
 25. The contraceptive composition of claim 21 wherein the CRISP polypeptide has at least about 40% structural identity to rat CRISP-1 (SEQ ID NO:2), or a biologically active analog thereof.
 26. The contraceptive composition of claim 21 wherein the CRISP polypeptide is rat CRISP-1 (SEQ ID NO:2).
 27. The contraceptive composition of claim 21 further comprising a spermicidal or antiviral agent. 